Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 07 May 2026 | Chiara Galiffa Cabinet member | Latest developments in EU-US relations | SRC |
| 01 Apr 2026 | Rainer Becker Director | Exchange of views on the Biotech Act and on the international pharmaceutical situation | — |
| 01 Apr 2026 | Rainer Becker Director | Exchange of views on the Biotech Act and on the international pharmaceutical situation | SRC |
| 24 Mar 2026 | Andreas Schwarz Cabinet member | Life sciences | SRC |
| 24 Mar 2026 | Ann-Sofie Ronnlund Cabinet member | Life sciences | SRC |
| 24 Mar 2026 | Patricia Reilly Cabinet member | Exchange on Biotech Act and strategic policy issues | SRC |
| 24 Mar 2026 | Patricia Reilly Cabinet member | Exchange on Biotech Act and strategic policy issues | — |
| 24 Mar 2026 | Ann-Sofie Ronnlund Cabinet member | Life sciences | — |
| 20 Mar 2026 | Olivér Várhelyi Commissioner | Leiden Car-T site visit | SRC |
| 20 Mar 2026 | Olivér Várhelyi Commissioner | Leiden Car-T site visit | — |
| 22 Jan 2026 | Olivér Várhelyi Commissioner | Health Package – Biotech Act | SRC |
| 22 Jan 2026 | Olivér Várhelyi Commissioner | Health Package – Biotech Act | — |
| 22 Jan 2026 | Laszlo Kristoffy Cabinet member | Health Package – Biotech Act | — |
| 05 Dec 2025 | Rainer Becker Director | The aim of the meeting was to discuss the possible improvements to the Clinical Trials Regulation, IP frameworks and cell therapy in the Biotech Act | — |
| 05 Dec 2025 | Rainer Becker Director | The aim of the meeting was to discuss the possible improvements to the Clinical Trials Regulation, IP frameworks and cell therapy in the Biotech Act | SRC |
| 18 Nov 2025 | Patricia Reilly Cabinet member | Biotechnology acts | SRC |
| 18 Nov 2025 | Patricia Reilly Cabinet member | Biotechnology acts | — |
| 30 Sept 2025 | Giulia Del Brenna Head of Unit | Issues and concerns related to the EU’s competitiveness in this sector, in particular regarding European legislation, U.S. tariffs on pharmaceuticals, and intellectual property. | SRC |
| 30 Sept 2025 | Giulia Del Brenna Head of Unit | Issues and concerns related to the EU’s competitiveness in this sector, in particular regarding European legislation, U.S. tariffs on pharmaceuticals, and intellectual property. | — |
| 17 Sept 2025 | Rainer Becker Director | Exchange on clinical trials in the context of the upcoming proposal for an EU Biotech Act | SRC |
| 17 Sept 2025 | Rainer Becker Director | Exchange on clinical trials in the context of the upcoming proposal for an EU Biotech Act | — |
| 08 Dec 2016 | Annika Nowak Cabinet member | HTA, HSPA | SRC |
| 08 Dec 2016 | Juho Romakkaniemi Cabinet member | Innovation and investment | SRC |
| 08 Dec 2016 | Juho Romakkaniemi Cabinet member | Innovation and investment | — |
| 08 Dec 2016 | Annika Nowak Cabinet member | HTA, HSPA | — |
Mission & Goals
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
EU Legislative Interests
28th Regime for Innovative Companies European Innovation Act Public Procurement Act European Research Area Act European Biotech Act I European Biotech Act II Omnibus on taxation Interest and Royalties Directive (Council Directive 2003/49/EC) Tax Merger Directive (Council Directive 2009/133/EC) Parent-Subsidiary Directive (Council Directive 2011/96/EU) Anti-Tax Avoidance Directive (Council Directive (EU) 2016/1164) Tax Dispute Resolution Mechanisms Directive (Council Directive 2017/1852). Framework for Income Taxation (BEFIT) Communication on better regulation Update of antitrust procedural rules Anti-corruption strategy Review of the anti-fraud architecture Evaluation of the customs enforcement of intellectual property rights The AI act The Apply AI Strategy Data governance: EHDS Cloud and AI Development Act Quantum Act Gender equality strategy 2026-2030 UWWTD PFAS EU economic governance framework Corporate sustainability reporting and due diligence Patent package Screening of foreign investments System of own resources of the European Union Multiannual financial framework Trade and Economic Security Advanced Therapy Medicinal Products Capital Markets Union
Communication Activities
BMS is a member of the All.Can initiative https://www.all-can.org/about-us/ Blood and Beyond https://bloodandbeyond.com/ Cardiomyopathies Matter cardiomyopathiesmatter.org BMS Linked-In Profile (Bristol Myers Squibb EU Policy) BMS EU policy website (www.eupolicy.bms.com).
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
European Federation of Pharmaceutical Industries and Associations (EFPIA), EFPIA Oncology Platform, EFPIA Cardiovascular Health Platform, EFPIA Alzheimer's Platform, DigitalEurope, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Friends of Europe, American Chamber of Commerce to the EU, American European Community Association (AECA), European Patients' Forum, EURORDIS, TRANSFORM Alliance, Alliance for Regenerative Medicines (ARM)
Organisation Members
See above
Additional Information
Bristol Myers Squibb Belgium has a corporate sponsorship with the Alliance of Liberals and Democrats for Europe for 2025. The amount of that corporate sponsorship is 18,000 euros and it is treated as a political donation. Bristol Myers Squibb Belgium has a cooperation agreement with The Wilfried Martens Centre for European Studies for 2025. The amount of that cooperation agreement is 12,000 euros and it is treated as a political donation In 2025 the number of BMS staff involved in covered activities increased as a result of the ongoing revision of the EU General Pharmaceutical Legislation and in light of the new mandate of the European Commission and the European Parliament.
Connected Legislation